Andere Kunden interessierten sich auch für
![BEHANDLUNG VON LATE-ONSET-SYNDROMEN SEKUNDÄR ZU NEUROLEPTIKA]( "BEHANDLUNG VON LATE-ONSET-SYNDROMEN SEKUNDÄR ZU NEUROLEPTIKA")
BEHANDLUNG VON LATE-ONSET-SYNDROMEN SEKUNDÄR ZU NEUROLEPTIKA39,90 €![The Bitterest Pills]( "The Bitterest Pills")
The Bitterest Pills81,99 €![Sleep Motor Activity In Parkinsonian Syndromes At Onset]( "Sleep Motor Activity In Parkinsonian Syndromes At Onset")
Sleep Motor Activity In Parkinsonian Syndromes At Onset33,99 €![Pneumocystis Jiroveci pneumocystis]( "Pneumocystis Jiroveci pneumocystis")
Pneumocystis Jiroveci pneumocystis "CARINII", late discovery in a kidney transplant recipient26,99 €![Objective evaluation of LUTS secondary to BPH]( "Objective evaluation of LUTS secondary to BPH")
Objective evaluation of LUTS secondary to BPH39,99 €![Management of late obstetric brachial plexus palsy]( "Management of late obstetric brachial plexus palsy")
Management of late obstetric brachial plexus palsy42,99 €![EPS of Newer Antipsychotics on Schizophrenic Patients]( "EPS of Newer Antipsychotics on Schizophrenic Patients")
EPS of Newer Antipsychotics on Schizophrenic Patients26,99 €
Remission rates for late onset syndromes, a serious and disabling side effect of dopamine receptor blocking agents, are low overall. An accurate phenomenological classification of these syndromes is needed to tailor treatment. The recommended treatment options have a low level of evidence. Clozapine has proven to be effective in clinical practice, particularly in cases of resistant schizophrenia and late onset syndrome. Other therapeutic alternatives seem promising.